By Justin Petrone

Increasing demand for target enrichment products and cytogenetic arrays helped Roche NimbleGen post a 22 percent rise in third-quarter revenue, the firm said last week.

In comparison, Roche's broader Applied Science business, a segment of the company's diagnostics division that encompasses Roche NimbleGen, decreased 2 percent during the third quarter, while the diagnostics division grew 1 percent and company-wide sales were down 7 percent for the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.